Malignant Solid Neoplasm

Oncology·MeSH: Neoplasm Metastasis

46 drugs in development·10 companies·38 clinical trials

Drug Pipeline by Phase

Phase 3(7)

Drug	Company
Alpelisib	Relay Therapeutics, Inc. (RLAY)
EGFR-TKI inhibitor based on investigator's choice	Relay Therapeutics, Inc. (RLAY)
Neratinib Maleate	Relay Therapeutics, Inc. (RLAY)
Neratinib Maleate	Merus N.V. (MRUS)
Neratinib Maleate	ENANTA PHARMACEUTICALS INC (ENTA)
Niraparib	Merus N.V. (MRUS)
Panitumumab	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 2(28)

Drug	Company
Alpelisib	ADMA BIOLOGICS, INC. (ADMA)
Alpelisib	ENANTA PHARMACEUTICALS INC (ENTA)
Alpelisib	Merus N.V. (MRUS)
Binimetinib	ENANTA PHARMACEUTICALS INC (ENTA)
Binimetinib	Relay Therapeutics, Inc. (RLAY)
Copanlisib Hydrochloride	Relay Therapeutics, Inc. (RLAY)
Defactinib Hydrochloride	Relay Therapeutics, Inc. (RLAY)
FID-007	Fulgent Genetics Inc. (FLGT)
Ipatasertib	Relay Therapeutics, Inc. (RLAY)
Ipatasertib	Merus N.V. (MRUS)
Larotrectinib Sulfate	Relay Therapeutics, Inc. (RLAY)
Leucovorin	Relay Therapeutics, Inc. (RLAY)
Leucovorin	ADMA BIOLOGICS, INC. (ADMA)
Leucovorin Calcium	Relay Therapeutics, Inc. (RLAY)
Neratinib Maleate	ADMA BIOLOGICS, INC. (ADMA)
Nilotinib Hydrochloride Monohydrate	Relay Therapeutics, Inc. (RLAY)
Niraparib	Black Diamond Therapeutics, Inc. (BDTX)
Olaparib	Relay Therapeutics, Inc. (RLAY)
Olaparib	IGM Biosciences, Inc. (IGMS)
Panitumumab	Relay Therapeutics, Inc. (RLAY)
Panitumumab	ADMA BIOLOGICS, INC. (ADMA)
PI3K-beta Inhibitor GSK2636771	Relay Therapeutics, Inc. (RLAY)
Selumetinib Sulfate	Relay Therapeutics, Inc. (RLAY)
Selumetinib Sulfate	ENANTA PHARMACEUTICALS INC (ENTA)
Sotorasib	ADMA BIOLOGICS, INC. (ADMA)
Sotorasib	Merus N.V. (MRUS)
Sotorasib	Relay Therapeutics, Inc. (RLAY)
Sotorasib	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1(10)

Drug	Company
aur107	PRF Technologies Ltd. (PRFX)
Avelumab	Accustem Sciences Inc. (ACUT)
BET Bromodomain Inhibitor ZEN-3694	Relay Therapeutics, Inc. (RLAY)
Edodekin alfa	ENANTA PHARMACEUTICALS INC (ENTA)
Eribulin	IGM Biosciences, Inc. (IGMS)
Niraparib	PTC THERAPEUTICS, INC. (PTCT)
Pemetrexed	IGM Biosciences, Inc. (IGMS)
Selinexor	IGM Biosciences, Inc. (IGMS)
Topotecan	IGM Biosciences, Inc. (IGMS)
Tuvusertib	Accustem Sciences Inc. (ACUT)

Phase 4(1)

Drug	Company
Leucovorin Calcium	IGM Biosciences, Inc. (IGMS)

BioSniper tracks 46 drugs in development for Malignant Solid Neoplasm across 10 companies.

There are 38 clinical trials targeting Malignant Solid Neoplasm tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.